Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

NCT00082836 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]